In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

William Masters

Graduate Fellow

London, UK

Latest From William Masters

Snapshot: April Highlights

A selection of articles you might have missed from April 2021, including exclusive interviews with industry leaders and a deeper dive into drug development and R&D.

Business Strategies Companies

Execs On The Move, April 2021

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Appointments BioPharmaceutical

Alchemab Targets ‘List Of The Worst-Served Diseases’

In an exclusive interview, Alchemab CEO Alex Leech talks to In Vivo about the company’s method of identifying naturally occurring antibodies to target high unmet needs in oncology, neurodegeneration and infectious diseases.

Financing Innovation

Novo Ventures Remains Bullish After ‘Very Active’ Year

In this latest installment of VC playbook, In Vivo speaks to Naveed Siddiqi, senior partner at Novo Ventures. He discusses the group’s strategy, the European investment outlook for life sciences and how COVID-19 has permanently shifted perceptions of the biopharma industry.

VC Playbook Business Strategies

Pandemic Puts A Spotlight On Counterfeit Drugs

As the ongoing COVID-19 pandemic forces health care to go digital, opportunities for fraud have proliferated. In Vivo explores the risks, the steps regulators are taking and how companies are looking to provide innovative solutions to help secure manufacturing supply chains.

C-Suite Speaks Drug Safety

Snapshot: March Highlights

A selection of articles you might have missed from March 2021, including exclusive interviews with industry leaders and a deeper dive into drug development and R&D.

Business Strategies Companies
See All
UsernamePublicRestriction

Register